Pharm

Phenobarbital

search

Phenobarbital

  • Pharmacology
  1. Mechanism
    1. GABA A Receptor Agonist
    2. See Barbiturates for more detalied mechanism description
  2. Pharmacokinetics
    1. Half-Life: 53 to 140 hours (very long, self tapering in withdrawal)
    2. Onset (IV): 5 minutes
    3. Peak Effect (IV): 30 minutes
  • Safety
  1. Pregnancy Category D
  2. Lactation: Not safe
  3. FDA Controlled Substance IV
  4. Therapeutic level: 15-40 mg/ml
  5. May be less addictive than Valium in outpatient withdrawal protocols
  • Metabolism
  1. Liver Metabolism
  2. Renal Dosing: Decrease to twice daily for moderate to severe Renal Insufficiency
  • Adverse Effects
  1. Serious
    1. Respiratory depression or apnea
      1. Intravenous dosing is higher risk for respiratory depression
      2. Avoid combining with Benzodiazepines or Opioids (see below)
    2. Withdrawal
      1. Avoid abruptly stopping
    3. Stevens-Johnson Syndrome
    4. Angioedema
    5. Suicidality
    6. Blood dyscrasias (Megaloblastic Anemia, Thrombocytopenia)
  2. Common
    1. Somnolence
    2. Bradycardia
    3. Nausea or Vomiting
    4. Dizziness, Nystagmus or Ataxia
    5. Decreased cognitive function
  • Drug Interactions
  1. CNS Depressants (Benzodiazepines, Opioids)
    1. Risk of respiratory depression or apnea
  • Dosing
  1. Precautions
    1. Avoid IV infusion >60 mg/min
  2. Status Epilepticus
    1. Phenobarbital 20-30 mg/kg IV (infusion rate <=100 mg/min)
      1. Repeat dosing at 10 mg/kg every 1 hour as needed
  3. Epilepsy
    1. Phenobarbital 3 to 6 mg/kg/day divided 2-3 times daily, up to 50-100 mg orally twice to three times daily
  4. Alcohol Withdrawal
    1. Phenobarbital 5-10 mg/kg IBW up to 130 to 260 mg every 20-30 minutes titrating to light sedation
    2. Nisavic (2019) Psychosomatics 60(5):458-67 [PubMed]
    3. Nelson (2019) Am J Emerg Med 37(4):733-6 [PubMed]
    4. Tidwell (2018) Am J Crit Care 27(6):454-60 [PubMed]
  • References
  1. (2020) Pharmacopeia, Tarascon, accessed on IOS 4/9/2021
  2. Cunningham and LoVecchio (2021) Crit Dec Emerg Med 35(4): 28